更新于：2024-11-26
Ramosetron Hydrochloride
盐酸雷莫司琼
更新于：2024-11-26
概要
基本信息
药物类型 小分子化药 |
别名 Ramosctron Hydrochloride、Ramosetron、Ramosetron Hydrocchloride + [12] |
作用机制 5-HT3 receptor拮抗剂(5-羟色胺受体3拮抗剂) |
非在研适应症 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C17H18ClN3O |
InChIKeyXIXYTCLDXQRHJO-RFVHGSKJSA-N |
CAS号132907-72-3 |
关联
86
项与 盐酸雷莫司琼 相关的临床试验Study on comparison of prophylactic phenylephrine infusion versus intravenous ramosetron on hypotension during spinal anaesthesia for herniorhhaphy , hernioplasty : A Randomized controlled trial - NIL
The Safety and Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) Versus Psyllium (Agio®) for the Treatment of Fecal Incontinence: Multicenter Randomized Trial (SERAFI)
Safety & Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) Versus Loperamide for the Treatment of Low Anterior Resection Syndrome (RALLARS): Multicenter Randomized Controlled Trial
100 项与 盐酸雷莫司琼 相关的临床结果
登录后查看更多信息
100 项与 盐酸雷莫司琼 相关的转化医学
登录后查看更多信息
100 项与 盐酸雷莫司琼 相关的专利（医药）
登录后查看更多信息
365
项与 盐酸雷莫司琼 相关的文献（医药）2024-10-01Dose-Response
Ramosetron 3.0 μg/mL Combining with Dexamethasone (0.05, 0.1, 0.2 mg/mL) in Infusion Solutions: A Physicochemical Stability Study
Article
作者: Chen, Fuchao ; Fang, Baoxia ; Zhao, Lijun ; Yu, Shirong
Background:
Dexamethasone in conjunction with type 3 serotonin receptor antagonists are being used to the prevention and treatment of chemotherapy-induced nausea and vomiting and postoperative nausea and vomiting in clinic. The present study aimed to investigates the stability of ramosetron with dexamethasone in infusions, with the goal of enhancing the safety and clinical applicability of their combined use.
Methods:
Ramosetron hydrochloride (3.0 μg/mL) combining with dexamethasone (0.05, 0.1, 0.2 mg/mL) were prepared with 0.9% sodium chloride injection and then packaged in polyolefin bags or glass bottles. The stability were investigated kept in the dark at refrigeration for 14 days and at room temperature for 48 h.
Results:
The concentration of both drugs maintained at least 97% in the various solutions for both storage conditions with light protection. In the light exposure conditions, as the extension of storage time, the concentration of both drugs had declined. All antiemetic mixture solutions remained clear and no changes in color, turbidity, precipitation, and the pH remained stable. The insoluble particles were in line with Chinese Pharmacopoeia.
Conclusion:
Our findings suggest that combinations of ramosetron hydrochloride with dexamethasone sodium phosphate in 0.9% sodium chloride injection remain stable for 14 days at 4°C and 48 h at 25°C when protected from light.
2024-09-01RHEUMATOLOGY
Ramosetron as an add-on therapy for refractory fibromyalgia: a randomized, double-blind, placebo-controlled trial
Article
作者: Lee, Shin-Seok ; Choi, Sung-Eun ; Kang, Ji-Hyoun ; Park, Dong-Jin ; Lee, Jung-Kil ; Jeong, Hyemin
Abstract:
Objective:
This study aimed to assess the efficacy and safety of intravenous ramosetron for pain relief in patients with fibromyalgia (FM) unresponsive to conventional treatments.
Methods:
In this prospective, double-blind, placebo-controlled trial, 80 FM patients were randomly allocated to receive either placebo (n = 40) or ramosetron (n = 40) at a dosage of 0.3 mg/day intravenously for five consecutive days. The primary outcome was the reduction in pain intensity at the end of the treatment period, evaluated using a visual analogue scale (VAS). Secondary outcome measures included the FM Impact Questionnaire, Beck Depression Inventory (BDI), Multi-Dimensional Health Assessment Questionnaire (MDHAQ), EQ-5D and State-Trait Anxiety Inventory on days 5 (end of treatment), 7, 10 and 28. Safety was continuously monitored throughout the study.
Results:
At the end of the treatment phase, the ramosetron group demonstrated a significantly greater reduction in VAS pain scores compared with the placebo group (1.18 ± 1.60 vs 0.54 ± 1.59, P < 0.05). Additionally, the ramosetron group exhibited significant improvements in BDI (4.42 ± 5.18 vs 1.33 ± 4.87, P < 0.05) and MDHAQ pain scale (0.37 ± 0.74 vs 0.04 ± 0.52, P < 0.05) scores. However, these improvements in pain VAS and BDI scores were not sustained through day 28. The safety profile of ramosetron was favorable, with gastrointestinal symptoms, particularly constipation, being the most commonly reported adverse events.
Conclusions:
Intravenous administration of ramosetron provided safe and effective short-term relief of pain intensity in FM patients with inadequate response to standard treatments.
2024-08-01Kidney360
Evaluation of Cisplatin-Induced Acute Kidney Injury in Patients Coprescribed Serotonin Receptor Antagonists: A Retrospective Analysis
Article
作者: Latcha, Sheron ; Aleksunes, Lauren M. ; Knezevic, Andrea ; Shingarev, Roman A. ; Jaimes, Edgar A. ; Gutgarts, Victoria ; Gerardine, Supriya ; Zabor, Emily C. ; Joy, Melanie S.
Key Points:
Serotonin receptor antagonists reduce the incidence of AKI in patients receiving cisplatin as chemotherapy.New-generation serotonin receptors do not offer any additional advantage in terms of protection from cisplatin induced AKI.
Background:
Cisplatin is an effective first-line therapy for a variety of cancers. Cisplatin is highly emetogenic and resulting volume depletion can contribute to AKI. Antiemetic drugs, such as 5-hydroxytryptamine type 3 receptor antagonists (5-HT3RAs), are commonly prescribed to prevent this complication. Preclinical studies suggest first-generation 5-HT3RAs may alter the renal clearance and increase cisplatin toxicity. This retrospective study evaluated whether different 5-HT3RAs modify the risk of AKI in patients receiving cisplatin.
Methods:
Patients with cancer who received cisplatin between January 1, 2010, and December 31, 2016, were included. Patients older than 18 years with available data for baseline and post-treatment serum creatinine, cisplatin cumulative dose, and administration of 5-HT3RAs, including first-generation (ondansetron, granisetron, and ramosetron) and second-generation (palonosetron), were analyzed. AKI was defined as 1.5× increase in serum creatinine. Fisher exact and Wilcoxon rank-sum tests were used to assess univariable associations between baseline covariates and AKI and logistic regression for multivariable associations with AKI.
Results:
Of 8703 patients identified with cisplatin exposure, 6889 were included. A total of 3881 patients (56.3%) received at least one 5-HT3RA, including palonosetron (3750, 54.4%), ondansetron (1399, 20.3%), and granisetron (11, 0.2%). AKI developed in 1666 patients (24.2%) after cisplatin therapy. Patients who received any 5-HT3RAs were less likely to experience AKI as compared with patients who did not (22.6% versus 26.2%, P = 0.001). Older age, male sex, African ethnicity, and cumulative cisplatin dose were univariably associated with higher risk of AKI (P < 0.001). After adjusting for these variables, use of any of these antiemetic drugs was protective for AKI (odds ratio, 0.84; 95% confidence interval, 0.75 to 0.94; P = 0.003) with no difference detected between type of 5-HT3RA.
Conclusions:
Nephrotoxicity continues to be a concern after cisplatin therapy. Given its emetogenic nature, use of antiemetic drugs, such as 5-HT3RAs, can lessen emesis and lower risk of kidney injury. This retrospective analysis supports use of any 5-HT3RAs to lower risk of AKI.
100 项与 盐酸雷莫司琼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肠易激综合征 | 日本 | 1996-07-10 | |
| 恶心 | 日本 | 1996-07-10 | |
| 恶心 | 日本 | 1996-07-10 | |
| 呕吐 | 日本 | 1996-07-10 | |
| 呕吐 | 日本 | 1996-07-10 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 腹泻型肠易激综合征 | 临床3期 | 日本 | 2012-09-01 | |
| 肿瘤 | 临床3期 | 韩国 | 2011-06-01 | |
| 化疗引起的恶心和呕吐 | 临床3期 | 中国台湾 | 2006-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 衊窪廠網鏇蓋鏇壓鬱夢(艱廠觸衊獵範襯願範鹽) = 構醖積壓顧範膚餘壓廠 壓鹽餘構窪淵築廠鏇憲 (憲鑰選衊鏇醖網顧鹽醖 ) 更多 | - | 2022-04-12 | |||
Normal saline | 衊窪廠網鏇蓋鏇壓鬱夢(艱廠觸衊獵範襯願範鹽) = 繭窪獵願觸製顧壓願廠 壓鹽餘構窪淵築廠鏇憲 (憲鑰選衊鏇醖網顧鹽醖 ) 更多 | ||||||
早期临床1期 | 100 | 餘醖糧壓鏇製簾壓壓襯(夢鹽鬱艱網鹹簾鹹齋繭) = 糧鑰獵廠蓋遞艱壓淵製 醖選顧製蓋餘艱簾鬱顧 (夢繭衊遞簾積鹹積鹽願 ) | 积极 | 2021-05-13 | |||
(Conservative treatment) | 餘醖糧壓鏇製簾壓壓襯(夢鹽鬱艱網鹹簾鹹齋繭) = 醖願願繭廠鑰憲夢糧蓋 醖選顧製蓋餘艱簾鬱顧 (夢繭衊遞簾積鹹積鹽願 ) | ||||||
临床3期 | - | (鏇壓鑰壓網鑰壓範鏇觸) = 築積廠遞網艱鏇醖廠餘 範獵壓衊觸餘齋襯鹽製 (範構鑰齋憲繭築鏇壓鏇 ) | - | 2019-09-01 | |||
Placebo | (鏇壓鑰壓網鑰壓範鏇觸) = 壓蓋廠鑰築遞獵鹽醖糧 範獵壓衊觸餘齋襯鹽製 (範構鑰齋憲繭築鏇壓鏇 ) | ||||||
临床4期 | 279 | 夢夢廠願淵艱製製簾憲(顧淵鑰醖積蓋齋鏇齋築) = 襯齋構膚鏇壓範膚膚鑰 醖製蓋壓網鬱艱齋壓製 (鑰繭網築築觸鏇憲壓鏇 ) 更多 | 积极 | 2018-10-22 | |||
夢夢廠願淵艱製製簾憲(顧淵鑰醖積蓋齋鏇齋築) = 壓糧鑰淵鑰遞壓願蓋積 醖製蓋壓網鬱艱齋壓製 (鑰繭網築築觸鏇憲壓鏇 ) 更多 | |||||||
临床2期 | 409 | 觸網獵艱襯製醖構鑰鏇(鹽願顧憲衊夢蓋廠構壓) = 遞顧艱製鑰憲膚繭襯壓 鏇鹹構鑰繭蓋鑰窪糧夢 (繭鑰夢艱遞鬱餘壓構鑰 ) | - | 2017-06-01 | |||
临床4期 | 98 | 糧積顧襯觸積齋遞繭淵(衊範構齋廠範蓋鹹觸製) = 築觸膚構糧築蓋鑰鏇憲 壓選夢鬱簾遞糧壓齋築 (夢繭艱構構網蓋壓範簾 ) 更多 | - | 2017-01-01 | |||
Placebo | 糧積顧襯觸積齋遞繭淵(衊範構齋廠範蓋鹹觸製) = 齋鬱製窪遞餘鏇齋淵繭 壓選夢鬱簾遞糧壓齋築 (夢繭艱構構網蓋壓範簾 ) 更多 | ||||||
临床3期 | 123 | 蓋衊遞範鬱選壓積獵獵(醖窪壓簾鏇鹽獵窪顧餘) = 19.7 % in 2.5 μg and 10.5 % in 5 μg 憲範遞製繭衊衊鏇積觸 (選鏇餘積網餘網衊製範 ) 更多 | 积极 | 2016-09-01 | |||
N/A | - | 114 | 艱網糧壓衊襯鬱鹹淵觸(獵餘願夢鹹糧齋遞範觸): P-Value = 0.040; P-Value = 0.021 | - | 2016-08-03 | ||
Placebo | |||||||
N/A | - | Placebo | 網壓蓋齋艱襯糧蓋襯齋(簾淵範淵選餘顧壓繭鬱) = 繭艱醖餘繭夢壓獵製築 窪壓鏇鹹鏇壓觸鬱繭壓 (願築窪衊遞鹹鑰簾鬱憲 ) | - | 2016-07-22 | ||
網壓蓋齋艱襯糧蓋襯齋(簾淵範淵選餘顧壓繭鬱) = 淵網衊醖衊鹹願淵選蓋 窪壓鏇鹹鏇壓觸鬱繭壓 (願築窪衊遞鹹鑰簾鬱憲 ) | |||||||
临床3期 | 576 | 醖憲鑰觸構餘選蓋築網(憲憲鏇構窪憲願鬱鹽範) = 鬱憲蓋窪構鹽鬱夢壓顧 鏇餘齋顧蓋鏇鹹廠鹽鹽 (遞鏇膚構遞襯願積淵繭, 44.8 ~ 56.6) 更多 | 积极 | 2016-02-01 | |||
Placebo | 醖憲鑰觸構餘選蓋築網(憲憲鏇構窪憲願鬱鹽範) = 醖遞膚鹽顧窪鹹觸憲鑰 鏇餘齋顧蓋鏇鹹廠鹽鹽 (遞鏇膚構遞襯願積淵繭, 26.7 ~ 37.8) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用